Vivizon Pharmaceutical said it would lower the prices of 45 medicines from May 23.

The announcement follows the Supreme Court’s recent order to lower drug prices. The Ministry of Health and Welfare also noticed changing the maximum reimbursement rates for Vivozon drugs.

The court ordered Vivozon’s drug prices cut due to Inist Biopharma’s illegal rebates between 2007 and 2012, which occurred before Vivozon acquired Inist Biopharma. The name of the company at the time was JRP.

JRP received the confirmation of criminal punishment in June 2012 and a notice from the Health Insurance Review and Assessment Service to reduce drug prices in December 2016.

In 2017, before Vivozon’s takeover, Inist Biopharma filed a request with a court to cancel the HIRA’s plan to cut the maximum drug reimbursement prices. The company went through the second and the third trial in 2018 and 2019, respectively. However, the Supreme Court decided to cut drug prices in July 2019.

“The announcement is the final results of the lawsuit that started five years ago. The company will follow the order without raising any different opinions, " Vivozon Pharmaceutical's official said. “We were aware of this issue at the acquisition of Inist Biopharma. We will take full responsibility as an acquirer.”

Vivozon Pharmaceutical makes and sells finished pharmaceutical products. The company was acquired by Vivozon Healthcare and joined Vivozon Group in 2020.